SEP 4, 2026 · INTERVENTIONAL STUDY
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
ClinicalTrials.gov
This is a clinical trial registry record describing an expanded access program with no results reported; it documents planned access to an investigational drug for patients who cannot enroll in formal trials.
Reported
Primary conditionALK-positive non-small cell lung cancer (NS…
Investigational agentNeladalkib (NVL-655)
Program typeExpanded Access Program